Incyte sees growing opportunity in dermatology
June 9, 2023
Share
WILMINGTON – When researchers at biopharmaceutical firm Incyte discovered that their blockbuster small-molecule cancer drug could also treat dermatological conditions like vitiligo and eczema, it marked a sea change in the company’s course. Incyte secured the first U.S. Food & Drug Administration approval for a vitiligo treatment, Opzelura, last summer. Then in November, it doubled
Want to Read More?
Paid DBT subscribers get unlimited access to all Insider content and much more. Learn more in our Insider FAQ.
Already an Insider? Log In.
The U.S. Food and Drug Administration's approval of Incyte's Opzelura as its first treatment of vitiligo has opened the potential for the Wilmington company to hone in on the dermatological market. | PHOTO COURTESY OF INCYTE[/caption]
